Table 3

Primary and secondary outcomes

Linagliptin, n = 24,131Glimepiride, n = 24,131
N events (IR/1,000 PY)N events (IR/1,000 PY)HR (95% CI) Ref. = glimepiride
Primary composite cardiovascular outcome373 (26.7)458 (29.7)0.91 (0.79–1.05)
Secondary outcomes:
 Myocardial infarction111 (7.9)142 (9.2)0.87 (0.68–1.12)
 Stroke90 (6.4)120 (7.8)0.84 (0.64–1.11)
 All-cause mortality*186 (15.5)219 (16.6)0.96 (0.79–1.17)
 All-cause mortality in Medicare fee-for-service180 (19.5)211 (20.3)0.97 (0.79–1.18)
  • IR, incidence rate; PY, patient-years; Ref., reference.

  • *The availability of mortality information varied by database. Medicare fee-for-service included complete information on all-cause mortality, MarketScan only included information on in-hospital death, and no information on mortality was available in Clinformatics.